Gilead Sciences Portfolio holdings
Gilead Sciences is an American biopharmaceutical company that researches and develops antiviral drugs for HIV/AIDS, hepatitis B and C, influenza and COVID-19. Michael Riordan, a doctor who was then an associate at the venture firm Menlo Ventures, founded it in 1987 as Oligogen, a name pointing to oligonucleotides, small strands of DNA. Riordan used Oligogen only while clearing a trademark issue with a California nonprofit, and he took the Gilead name from the Balm of Gilead, which he first met in a Lanford Wilson play. Gilead discovered the flu drug Tamiflu and licensed it to Roche, and its 2011 purchase of Pharmasset brought it sofosbuvir, approved in 2013 as the hepatitis C treatment Sovaldi. In 2017 Gilead said it would acquire Kite Pharma as its entry into cell therapy, a deal that had produced two lymphoma treatments, Yescarta and Tecartus, by 2022.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Assembly Biosciences
ASMB
|
+$50.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOOKIPA Pharma
HOOK
|
+$2.35M |
| 2 |
Allogene Therapeutics
ALLO
|
+$1.31M |
| 3 |
Kalaris Therapeutics
KLRS
|
+$848K |
| 4 |
ImageneBio Inc
IMA
|
+$467K |
| 5 |
BRNS
Barinthus Biotherapeutics
BRNS
|
+$92.5K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.87% |
| 2 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.13B
| $579M | 32.31% |
16,707,477
| – | – |
2024 Q4
3 quarters
|
|
2
DELISTED
Arcellx
ACLX
| $552M | 30.8% |
6,720,803
| – | – |
2024 Q4
3 quarters
|
|
3
Arcus Biosciences
RCUS
$2.32B
| $427M | 23.86% |
31,424,760
| – | – |
2024 Q4
3 quarters
|
|
|
4
Assembly Biosciences
ASMB
$410M
| $115M | 6.44% |
4,505,391
+2,295,920
| +104% | +$50.4M |
2024 Q4
3 quarters
|
|
5
DELISTED
Merus
MRUS
| $42.6M | 2.38% |
452,527
| – | – |
2024 Q4
3 quarters
|
|
6
Tango Therapeutics
TNGX
$3.83B
| $40.8M | 2.28% |
4,854,443
| – | – |
2024 Q4
3 quarters
|
|
7
Kyverna Therapeutics
KYTX
$351M
| $24.8M | 1.38% |
4,126,119
| – | – |
2024 Q4
3 quarters
|
|
8
Xilio Therapeutics
XLO
$52.8M
| $7.67M | 0.43% |
650,389
| – | – |
2024 Q4
3 quarters
|
|
9
Cypherpunk Technologies Inc
CYPH
$321M
| $2.41M | 0.13% |
5,319,148
| – | – |
2024 Q4
3 quarters
|
|
|
10
Allogene Therapeutics
ALLO
$408M
| – | – |
-1,156,689
| Closed | -$1.31M | – |
|
|
BRNS
11
DELISTED
Barinthus Biotherapeutics
BRNS
| – | – |
-99,478
| Closed | -$92.5K | – |
|
|
12
DELISTED
HOOKIPA Pharma
HOOK
| – | – |
-1,875,945
| Closed | -$2.35M | – |
|
|
13
ImageneBio Inc
IMA
$46.5M
| – | – |
-29,045
| Closed | -$467K | – |
|
|
14
Kalaris Therapeutics
KLRS
$48.3M
| – | – |
-317,789
| Closed | -$848K | – |
|
Similar funds
Gilead Sciences's Q3 2025 Portfolio in Review
As of Q3 2025, Gilead Sciences held 14 positions worth $1.79B, up 40% from $1.28B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Gilead Sciences's Q3 2025 filing shows 1 increased and 5 closed positions. The largest sale was HOOKIPA Pharma, an estimated $2.35M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.
- Gilead Sciences added most to Assembly Biosciences in Q3 2025, an estimated $50.4M increase.
- Gilead Sciences fully exited HOOKIPA Pharma in Q3 2025, selling an estimated $2.35M.
- Gilead Sciences's ten largest holdings make up 100% of its $1.79B portfolio in Q3 2025.
- Gilead Sciences opened 0 new positions and closed 5 in Q3 2025.
- Gilead Sciences's portfolio value rose 40% quarter-over-quarter to $1.79B.
Based on Gilead Sciences's 13F filing for Q3 2025, filed 13 Nov 2025.